03.06.23 -- Cell And Gene Therapy: A Hub To Remember

It is a challenge for companies to reliably manufacture cell and gene therapeutics. One persistent problem is residual host cell DNA contamination. Explore why purification is so important, the limits of common molecular methods, and how Droplet Digital™ PCR could form the future of molecular detection.

Cell cultures are vulnerable to contaminants such as bacteria yeasts, molds, viruses, and mycoplasma. Some of those contaminants are harder to detect than others. Explore the benefits of Droplet Digital PCR, the mycoplasma detection kit workflow, and how you can achieve higher sensitivity, quantitative readout reports, and more.

Cell and gene therapies begin their development with the help of a host cell line, but before the product can be administered to a patient, any trace of the host cell DNA must be removed. Learn about HEK293 residual DNA, the effects of its contamination, and a currently available detection method.

RNA-based biotherapeutics have opened a new door to therapeutics discovery and development and are positioned to provide a rapid, cost-effective, and readily adaptable way to address previously “undruggable” targets. Take a look at this brief history of RNA-based therapy and how Droplet Digital™ PCR supports this field of work.

Explore the future of cell and gene therapy with eight experts who explain regulatory expectations & guidelines around AAV gene therapy, tips for meeting regulatory guidelines, harnessing analytical technologies to modify your AAV development workflow, and trends in AAV-based gene therapies and gene-modified cell therapy.